Skip to content
Research library

Clinical research overview

This library brings together peer-reviewed studies on Mesenchymal Stem Cells (MSCs) across a wide range of medical indications. Each study contributes to a deeper understanding of how MSCs support repair, regeneration, and immune balance in the body.
Crohn's disease Aging frailty Osteoarthritis
Acute respiratory disease syndrome Graft versus host disease (GvHD) Multiple sclerosis Liver cirrhosis Diabetes type II Diabetes type I Chronic low back pain Chronic obstructive pulmonary disease (COPD) Alzheimer's disease Rheumatoid arthritis

Diabetes type I

Clinical studies are evaluating Mesenchymal Stem Cells (MSCs) in Type 1 diabetes, focusing on how they may influence immune pathways and help preserve pancreatic function. Type 1 diabetes is an autoimmune disease in which glutamic acid decarboxylase (GAD) is a major auto-antigen targeted by the immune system and thereby destroys insulin-producing beta cells in the pancreas. This leads to insulin deficiency, high blood sugar and death if untreated. Even if adequately treated long-term complications often arise affecting multiple organ-systems of the body being an important contributor to morbidity. MSC trials are still early and primarily exploratory, but they are contributing to the broader field of autoimmune and metabolic disease research.

One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study

Jing Lu, et al.
The preservation or restoration of β cell function in type 1 diabetes (T1D) remains as an attractive and challengeable therapeutic target. Mesenchymal stromal cells (MSCs) are multipotent cells with high capacity of immunoregulation, which emerged as a promising cell-based therapy for many immune disorders. The objective of this study was to examine the efficacy and safety of one repeated transplantation of allogeneic MSCs in individuals with T1D.
More
Read study

Allogenic Adipose Tissue-Derived Stromal/Stem Cells and Vitamin D Supplementation in Patients With Recent-Onset Type 1 Diabetes Mellitus: A 3-Month Follow-Up Pilot Study

Debora B Araujo, et al.
To evaluate the short term safety and potential therapeutic effect of allogenic adipose tissue-derived stromal/stem cells (ASCs) + cholecalciferol in patients with recent-onset T1D.
More
Read study

Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial

Mahmoud Izadi, et al.
Type-1 diabetes (T1D) occurs following autoimmune-induced pancreatic beta cells death. Among several treatment modalities, mesenchymal stem cells (MSCs) transplantation is promising for autoimmune disorders due to immunomodulation, regeneration, and migration to damaged tissue upon systemic injection. This study assessed the safety and efficacy of intravenous injection of autologous bone marrow-derived MSCs in newly diagnosed T1D patients.
More
Read study